We have served over 800 satisfied customers. Our clients include investors (about 45%) and companies (about 55%).
Have a look at our non-confidential list of investors and companies to get an idea of what we can do for you.
Investors
Aravis
Switzerland
BIoM AG
Germany
Celtic Pharma Holdings II L.P
UK
Esperante
UK
European Investment Bank (EIB)
Luxembourg
Family Office
Germany
GSK CEEDD
UK
HP / NCICube
Switzerland
Novartis Venture Fund
Switzerland
Undisclosed
UK and France
Unirisco / Uninvest
Spain
Companies
4SC
Germany
APR Applied Pharma Research
Switzerland
Arpida / Evolva
Switzerland
Axxam SpA
Italy
Biolytix AG
Switzerland
ChemOvation
UK
Discovery Genomics Inc.
USA
Esbatec
Switzerland
Fachhochschule Salzburg
Austria
Genedata AG
Switzerland
Photonfocus AG
Switzerland
Sinus Point AG
Switzerland
Swiss Pharma Contract
Switzerland
Thommen Medical AG
Switzerland
Viron Therapeutics Inc.
Canada
VitaPlant AG
Switzerland
What our client says
Our experience with Venture Valuation was collegial, even during the occasional differences of perspective, which are inevitable. We found the ultimate valuation to be fair and comprehensive.
Venture Valuation helped us to independently value a large number of companies in a structured and reproduceable manner, providing transparency and clear basis for decisions. Great team to work with!
We found that the reports were of excellent quality. We can recommend Venture Valuation to all parties that have a need for valuation. We are considering to request further valuations from Venture Valuation.
Professional service, great interaction with the client, delivery of report according to timelines
Straight forward interaction with the Venture Valuation's team.
Impressed by fast turn around and delivery in time of a complex content case.
In addition to a report which exceeded expectations, the whole process pushed us to review some of the options we initially considered. I strongly recommend the exercise.
Venture Valuation provides a well-structured, independent opinion on the company's valuation, supported by a detailed report demonstrating their understanding of the company.
